<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02685072</url>
  </required_header>
  <id_info>
    <org_study_id>1504015618</org_study_id>
    <secondary_id>R21CA198187</secondary_id>
    <nct_id>NCT02685072</nct_id>
  </id_info>
  <brief_title>Progesterone Augmentation of Nicotine Replacement Therapy Study</brief_title>
  <acronym>PANS</acronym>
  <official_title>Progesterone Augmentation of Nicotine Replacement Therapy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a double-blind, placebo-controlled, pilot, randomized clinical trial. A total of
      50 women who smoke and have regular menstrual cycles will be randomized to either
      progesterone (200 mgs BID) + Transdermal Nicotine Patch (TNP) or placebo + TNP for 8 weeks.
      TNP will be tapered after 4-6 weeks. Progesterone or matching placebo will be discontinued at
      the end of Week 8. All participants will also be provided behavioral treatment for smoking
      cessation. Participants will be inducted onto progesterone (or placebo) + TNP over a one-week
      period (Week 1) during the mid luteal phase, within a week before menses and the target quit
      date will be set for the 5 (+/-2) days after onset of menses. Participants will have
      post-trial follow-up visits at 1 and 3 months.The main study outcomes will be self- report of
      smoking abstinence, biochemically verified smoking abstinence, measures of cigarette craving
      and nicotine withdrawal, and measures of response inhibition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to determine if modifying the hormonal milieu of the menstrual cycle,
      through administration of exogenous progesterone, will improve the effectiveness of
      treatments for smoking cessation in women. Progesterone, a gonadal hormone, is used
      clinically for treatment of endometrial hyperplasia, amenorrhea, dysfunctional uterine
      bleeding, and for assisted reproduction in women. Progesterone also shows promise for the
      treatment of multiple central nervous system disorders including cocaine addiction, seizure
      disorder, and traumatic brain injury. As the next step, the investigators seek to determine
      if progesterone augments standard smoking cessation treatments (e.g., NRT) in regularly
      cycling women. The investigators hypothesize that co-treatment with progesterone, compared to
      placebo, will enhance the effectiveness NRT for smoking cessation. To test this hypothesis,
      the investigators propose an 8-week, double-blind, placebo-controlled clinical trial, which
      will randomize 50 smokers using a 1:1 assignment ratio to 400 mg/day progesterone or placebo.
      Consistent with the Clinical Practice Guidelines, all participants will also receive
      transdermal nicotine patch (TNP) plus brief counseling for smoking cessation during the study
      participation.

      Specific Aim #1: To determine if progesterone +TNP is superior to placebo +TNP for prolonged
      and 7-day point prevalence of smoking abstinence rates at the end of 8 weeks of treatment and
      at 1 and 3 month follow-up time points. The investigators will also evaluate the safety and
      tolerability of progesterone treatment, compared to placebo. Our co-primary outcome measures
      will be 7-day point prevalence of smoking abstinence and breath CO at the end of treatment
      and 1- and 3-months after the end of the trial. Specific Aim #2: To determine if progesterone
      + TNP treatment, compared to placebo + TNP, improves response inhibitory function, as
      assessed by the Stroop, The Go/No Go task, and the Digit Symbol Task. Specific Aim # 3: To
      determine if progesterone + TNP treatment, compared to placebo + TNP, leads to a greater
      reduction in cigarette craving and nicotine withdrawal symptoms, as assessed by the
      Questionnaire on Smoking Urges-Brief (QSU-B) and the Minnesota Nicotine Withdrawal Scale
      (MNWS), respectively. Specific Aim #4: To evaluate with affective changes, as shown on the
      Positive and Negative Affect Schedule, mediates the effects of progesterone on smoking
      abstinence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2016</start_date>
  <completion_date type="Actual">March 12, 2018</completion_date>
  <primary_completion_date type="Actual">December 18, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence of Smoking Abstinence</measure>
    <time_frame>end of 8 weeks of treatment</time_frame>
    <description>The 7-day point prevalence is defined by self-reported smoking abstinence for the last 7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carbon Monoxide &lt;10 Ppm</measure>
    <time_frame>end of 8 weeks of treatment</time_frame>
    <description>Smoking abstinence measured by breath CO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon Monoxide &lt;10 Ppm</measure>
    <time_frame>1 month follow up</time_frame>
    <description>Smoking abstinence measured by breath CO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon Monoxide &lt;10 Ppm</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Smoking abstinence measured by breath CO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stroop Measure of Inhibitory Function</measure>
    <time_frame>baseline and week 2</time_frame>
    <description>The Stroop test assesses cognitive processing. The Level 3 Stroop Throughput score incorporates both accuracy and speed. In Level 3 of the Stroop test, a series of words representing colors are shown in a font color that is incongruent with the word (e.g. RED would be shown in blue font). Users are asked to press a response key associated with the color of the font, not the written word. Quicker and more accurate responses lead to higher scores. The lowest possible score is 0 (no correct responses). There is no defined maximum score, as the score depends upon both response time and number of correct responses. A Level 3 Stroop Throughput change score was calculated by subtracting baseline score from week 2 score. Higher positive scores represent greater improvement in scores at week 2 relative to baseline, and lower negative scores represent greater decline in scores from baseline to week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Go/No Go Task Measure of Inhibitory Function</measure>
    <time_frame>baseline and week 2</time_frame>
    <description>Week 2 minus baseline. This task assesses the ability to withhold responses to an infrequently occurring target (No-Go trials). A total of 225 single digits (25 x 9 digits) are presented on a computer monitor for 250 ms each, immediately followed by a mask for 900 ms. Subjects must press a spacebar in response to every digit except the &quot;3&quot;.
Go/No Go score is calculated as separation between the means of the signal and the noise distributions and is reported in standard deviation units, representing an overall indicator of performance since it accounts for correct responses and incorrect responses. Higher scores represent a better outcome. For the change score, higher positive scores represent greater improvement in scores between baseline and week 2, and lower negative scores represent greater decline in scores between baseline and week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Digit Symbol Task Measure of Inhibitory Function</measure>
    <time_frame>baseline and week 2</time_frame>
    <description>The Code Substitution Test (a computerized adaptation/variant of the Digit Symbol Substitution Test) is a test of psychomotor performance. The Code Substitution-Learning Throughput Score incorporates both accuracy and speed. During the learning phase of this test, users are continuously shown a row of 9 digits that are paired with a symbol (the pairings are constant). Users are presented with a series of individual pairings and are asked to press a response key to indicate if the pairing is correct or not. Quicker and more accurate responses lead to higher scores. The lowest possible score is 0 (no correct responses). There is no defined maximum score, as the score depends upon both response time and number of correct responses. A change score was calculated by subtracting baseline score from week 2 score. Higher positive scores represent greater improvement in scores at week 2 relative to baseline, and lower negative scores represent greater decline in scores from baseline to week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>Baseline</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>Week 2</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>Week 3</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>Week 4</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>Week 5</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>Week 6</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>Week 7</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>Week 8</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>1 month follow up</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) Total Score</measure>
    <time_frame>3 month follow up</time_frame>
    <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged Abstinence Post Trial</measure>
    <time_frame>1-month follow-up after end of treatment</time_frame>
    <description>Abstinence from 2 weeks post quit date to the one month follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged Abstinence Follow up</measure>
    <time_frame>3-month follow-up after end of treatment</time_frame>
    <description>Abstinence from 2 weeks post quit date to 3 month follow up (total of 6-8 weeks during the trial and 3 month follow up)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>TNP + Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNP + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Transdermal Nicotine Patch + Placebo (for Progesterone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone (200 mgs BID)</intervention_name>
    <description>Transdermal Nicotine Patch (TNP) + Progesterone</description>
    <arm_group_label>TNP + Progesterone</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TNP + Placebo</description>
    <arm_group_label>TNP + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 - 45

          -  Smoking at least 5 cigarettes/ day for at least one year

          -  Regular menstrual cycles every 24-36 days for the previous 6 months

          -  Motivated to quit smoking (i.e., a rating of at least &quot;7 &quot;on a 10-point scale where 1
             is not at all motivated and 10 is extremely motivated)

          -  In good health

          -  Using an acceptable, non-hormonal birth control

        Exclusion Criteria:

        A history of major medical or psychological illnesses including:

          -  liver disease

          -  heart disease

          -  diabetes

          -  malignancy including history of breast cancer

          -  deep vein thrombosis

          -  blood coagulation problems including a history or family history of thrombophilia

          -  liver failure

          -  cervical intra-epithelial lesions III or greater that are untreated

          -  other medical conditions that the physician investigators deems will make study
             participation unsafe for the subject

          -  current or past history bipolar disorder or schizophrenia

          -  current diagnosis of major depression

          -  panic disorder or post-traumatic stress disorder

          -  active drug (non-nicotine) and/or alcohol dependence

          -  currently undergoing treatment with another pharmacological agent for smoking
             cessation

          -  regular use of sedating medications including sleeping aids, antihistamines, and
             others use of nicotine from cigars, pipes, chewing tobacco

          -  pregnant

          -  breast- feeding or intending to become pregnant within 6 months

          -  allergy to nicotine patch or progesterone

          -  allergy to peanuts or other nuts.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Yonkers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine, Department of Psychiatry</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <results_first_submitted>January 29, 2019</results_first_submitted>
  <results_first_submitted_qc>July 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine Cessation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>we will only make aggregate de-identified data available</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02685072/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TNP + Progesterone</title>
          <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
        </group>
        <group group_id="P2">
          <title>TNP + Placebo</title>
          <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 2 Visit</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 3 Visit</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 4 Visit</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 5 Visit</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 6 Visit</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 7 Visit</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 8 Visit</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22">Week 8 data were collected at the 1-month follow-up for 1 participant</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1-Month Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>3-Month Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TNP + Progesterone</title>
          <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
        </group>
        <group group_id="B2">
          <title>TNP + Placebo</title>
          <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" spread="7.6"/>
                    <measurement group_id="B2" value="33.0" spread="8.0"/>
                    <measurement group_id="B3" value="32.6" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIxed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="7.0"/>
                    <measurement group_id="B2" value="13.2" spread="7.3"/>
                    <measurement group_id="B3" value="12.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Motivation to quit smoking</title>
          <description>Participants were asked on a scale from 1 (not motivated at all) to 10 (extremely motivated), how motivated are you to quit smoking?</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" spread="1.1"/>
                    <measurement group_id="B2" value="8.9" spread="1.3"/>
                    <measurement group_id="B3" value="8.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lives with smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lives with smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Does not live with smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence of Smoking Abstinence</title>
        <description>The 7-day point prevalence is defined by self-reported smoking abstinence for the last 7 days.</description>
        <time_frame>end of 8 weeks of treatment</time_frame>
        <population>Participants (n=13 in TPN + Progesterone; n=9 in TPN + Placebo) missing outcome data were coded as not abstinent.</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence of Smoking Abstinence</title>
          <description>The 7-day point prevalence is defined by self-reported smoking abstinence for the last 7 days.</description>
          <population>Participants (n=13 in TPN + Progesterone; n=9 in TPN + Placebo) missing outcome data were coded as not abstinent.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>abstinent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>not abstinent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3253</p_value>
            <method>Chi-squared</method>
            <method_desc>degrees of freedom =1</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5818</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1968</ci_lower_limit>
            <ci_upper_limit>1.7202</ci_upper_limit>
            <estimate_desc>Odds ratio represents odds of smoking abstinence in TPN + progesterone group versus TPN + placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbon Monoxide &lt;10 Ppm</title>
        <description>Smoking abstinence measured by breath CO</description>
        <time_frame>end of 8 weeks of treatment</time_frame>
        <population>Participants (n=13 in TPN + Progesterone; n=10 in TPN + Placebo) missing breath CO were coded as ≥ 10 ppm (positive for smoking).</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Carbon Monoxide &lt;10 Ppm</title>
          <description>Smoking abstinence measured by breath CO</description>
          <population>Participants (n=13 in TPN + Progesterone; n=10 in TPN + Placebo) missing breath CO were coded as ≥ 10 ppm (positive for smoking).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CO &lt;10 ppm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>CO ≥ 10 ppm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8944</p_value>
            <method>Chi-squared</method>
            <method_desc>degrees of freedom = 1</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0781</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3550</ci_lower_limit>
            <ci_upper_limit>3.2744</ci_upper_limit>
            <estimate_desc>Odds ratio represents odds of CO &lt; 10 (negative for smoking) in TPN + progesterone versus TPN + placebo groups</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbon Monoxide &lt;10 Ppm</title>
        <description>Smoking abstinence measured by breath CO</description>
        <time_frame>1 month follow up</time_frame>
        <population>Participants (n=14 in TPN + progesterone; n=9 in TPN + placebo) missing breath CO data were coded as &gt; 10 ppm (positive for smoking).</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Carbon Monoxide &lt;10 Ppm</title>
          <description>Smoking abstinence measured by breath CO</description>
          <population>Participants (n=14 in TPN + progesterone; n=9 in TPN + placebo) missing breath CO data were coded as &gt; 10 ppm (positive for smoking).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CO &lt;10 ppm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>CO ≥ 10 ppm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6620</p_value>
            <method>Chi-squared</method>
            <method_desc>degrees of freedom = 1</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7619</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2247</ci_lower_limit>
            <ci_upper_limit>2.5838</ci_upper_limit>
            <estimate_desc>Odds ratio represents odds of CO &lt; 10 ppm (negative for smoking) in TPN + progesterone versus TPN + placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbon Monoxide &lt;10 Ppm</title>
        <description>Smoking abstinence measured by breath CO</description>
        <time_frame>3 month follow up</time_frame>
        <population>Participants (n=14 in TPN + progesterone; n=9 in TPN + placebo) missing breath CO data were coded as &gt; 10 ppm (positive for smoking).</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Carbon Monoxide &lt;10 Ppm</title>
          <description>Smoking abstinence measured by breath CO</description>
          <population>Participants (n=14 in TPN + progesterone; n=9 in TPN + placebo) missing breath CO data were coded as &gt; 10 ppm (positive for smoking).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CO &lt;10 ppm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>CO ≥ 10 ppm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8661</p_value>
            <method>Chi-squared</method>
            <method_desc>degrees of freedom = 1</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9130</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3171</ci_lower_limit>
            <ci_upper_limit>2.6287</ci_upper_limit>
            <estimate_desc>Odds ratio represents odds of CO &lt; 10 ppm (negative for smoking) in TPN + progesterone versus TPN + placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stroop Measure of Inhibitory Function</title>
        <description>The Stroop test assesses cognitive processing. The Level 3 Stroop Throughput score incorporates both accuracy and speed. In Level 3 of the Stroop test, a series of words representing colors are shown in a font color that is incongruent with the word (e.g. RED would be shown in blue font). Users are asked to press a response key associated with the color of the font, not the written word. Quicker and more accurate responses lead to higher scores. The lowest possible score is 0 (no correct responses). There is no defined maximum score, as the score depends upon both response time and number of correct responses. A Level 3 Stroop Throughput change score was calculated by subtracting baseline score from week 2 score. Higher positive scores represent greater improvement in scores at week 2 relative to baseline, and lower negative scores represent greater decline in scores from baseline to week 2.</description>
        <time_frame>baseline and week 2</time_frame>
        <population>Includes people who completed Stroop Test at both baseline and Week 2 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stroop Measure of Inhibitory Function</title>
          <description>The Stroop test assesses cognitive processing. The Level 3 Stroop Throughput score incorporates both accuracy and speed. In Level 3 of the Stroop test, a series of words representing colors are shown in a font color that is incongruent with the word (e.g. RED would be shown in blue font). Users are asked to press a response key associated with the color of the font, not the written word. Quicker and more accurate responses lead to higher scores. The lowest possible score is 0 (no correct responses). There is no defined maximum score, as the score depends upon both response time and number of correct responses. A Level 3 Stroop Throughput change score was calculated by subtracting baseline score from week 2 score. Higher positive scores represent greater improvement in scores at week 2 relative to baseline, and lower negative scores represent greater decline in scores from baseline to week 2.</description>
          <population>Includes people who completed Stroop Test at both baseline and Week 2 visits.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="24.7"/>
                    <measurement group_id="O2" value="-5.0" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.1</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
            <estimate_desc>(Placebo + TPN) - (Progesterone + TPN)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Go/No Go Task Measure of Inhibitory Function</title>
        <description>Week 2 minus baseline. This task assesses the ability to withhold responses to an infrequently occurring target (No-Go trials). A total of 225 single digits (25 x 9 digits) are presented on a computer monitor for 250 ms each, immediately followed by a mask for 900 ms. Subjects must press a spacebar in response to every digit except the &quot;3&quot;.
Go/No Go score is calculated as separation between the means of the signal and the noise distributions and is reported in standard deviation units, representing an overall indicator of performance since it accounts for correct responses and incorrect responses. Higher scores represent a better outcome. For the change score, higher positive scores represent greater improvement in scores between baseline and week 2, and lower negative scores represent greater decline in scores between baseline and week 2.</description>
        <time_frame>baseline and week 2</time_frame>
        <population>Includes participants who completed the Go/No Go task at both baseline and week 2 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Go/No Go Task Measure of Inhibitory Function</title>
          <description>Week 2 minus baseline. This task assesses the ability to withhold responses to an infrequently occurring target (No-Go trials). A total of 225 single digits (25 x 9 digits) are presented on a computer monitor for 250 ms each, immediately followed by a mask for 900 ms. Subjects must press a spacebar in response to every digit except the &quot;3&quot;.
Go/No Go score is calculated as separation between the means of the signal and the noise distributions and is reported in standard deviation units, representing an overall indicator of performance since it accounts for correct responses and incorrect responses. Higher scores represent a better outcome. For the change score, higher positive scores represent greater improvement in scores between baseline and week 2, and lower negative scores represent greater decline in scores between baseline and week 2.</description>
          <population>Includes participants who completed the Go/No Go task at both baseline and week 2 visits.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="2.33"/>
                    <measurement group_id="O2" value="0.50" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7910</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1480</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9747</ci_lower_limit>
            <ci_upper_limit>1.2707</ci_upper_limit>
            <estimate_desc>(placebo + TPN) - (progesterone + TPN)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Digit Symbol Task Measure of Inhibitory Function</title>
        <description>The Code Substitution Test (a computerized adaptation/variant of the Digit Symbol Substitution Test) is a test of psychomotor performance. The Code Substitution-Learning Throughput Score incorporates both accuracy and speed. During the learning phase of this test, users are continuously shown a row of 9 digits that are paired with a symbol (the pairings are constant). Users are presented with a series of individual pairings and are asked to press a response key to indicate if the pairing is correct or not. Quicker and more accurate responses lead to higher scores. The lowest possible score is 0 (no correct responses). There is no defined maximum score, as the score depends upon both response time and number of correct responses. A change score was calculated by subtracting baseline score from week 2 score. Higher positive scores represent greater improvement in scores at week 2 relative to baseline, and lower negative scores represent greater decline in scores from baseline to week 2.</description>
        <time_frame>baseline and week 2</time_frame>
        <population>Includes participants who completed the Code Substitution-Learning Test.at both baseline and week 2 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): Transdermal Nicotine Patch (TNP) + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Digit Symbol Task Measure of Inhibitory Function</title>
          <description>The Code Substitution Test (a computerized adaptation/variant of the Digit Symbol Substitution Test) is a test of psychomotor performance. The Code Substitution-Learning Throughput Score incorporates both accuracy and speed. During the learning phase of this test, users are continuously shown a row of 9 digits that are paired with a symbol (the pairings are constant). Users are presented with a series of individual pairings and are asked to press a response key to indicate if the pairing is correct or not. Quicker and more accurate responses lead to higher scores. The lowest possible score is 0 (no correct responses). There is no defined maximum score, as the score depends upon both response time and number of correct responses. A change score was calculated by subtracting baseline score from week 2 score. Higher positive scores represent greater improvement in scores at week 2 relative to baseline, and lower negative scores represent greater decline in scores from baseline to week 2.</description>
          <population>Includes participants who completed the Code Substitution-Learning Test.at both baseline and week 2 visits.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.95" spread="11.42"/>
                    <measurement group_id="O2" value="5.32" spread="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0065</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.71</ci_lower_limit>
            <ci_upper_limit>15.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="7.0"/>
                    <measurement group_id="O2" value="25.6" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="2.1"/>
                    <measurement group_id="O2" value="11.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>Week 2</time_frame>
        <population>Note: numbered analyzed does not equal 24</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <population>Note: numbered analyzed does not equal 24</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="7.1"/>
                    <measurement group_id="O2" value="24.4" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="1.9"/>
                    <measurement group_id="O2" value="11.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>Week 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="8.6"/>
                    <measurement group_id="O2" value="27.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="2.1"/>
                    <measurement group_id="O2" value="12.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" spread="7.4"/>
                    <measurement group_id="O2" value="26.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="1.3"/>
                    <measurement group_id="O2" value="11.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>Week 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="8.6"/>
                    <measurement group_id="O2" value="27.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="1.0"/>
                    <measurement group_id="O2" value="10.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="10.0"/>
                    <measurement group_id="O2" value="25.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="1.8"/>
                    <measurement group_id="O2" value="11.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>Week 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="9.1"/>
                    <measurement group_id="O2" value="24.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="3.2"/>
                    <measurement group_id="O2" value="10.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="10.4"/>
                    <measurement group_id="O2" value="26.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="2.7"/>
                    <measurement group_id="O2" value="10.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>1 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="8.7"/>
                    <measurement group_id="O2" value="26.4" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="1.1"/>
                    <measurement group_id="O2" value="11.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
        <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
        <time_frame>3 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) Total Score</title>
          <description>The PANAS questionnaire consists of 20 items that describe different feelings and emotions. Participants are asked to what extent they feel this way right now on 5-point scale ranging from 1 (very slightly or not at all) to 5 (extremely). Separate Positive Affect Scores and Negative Affect Scores were calculated from 10 items each. Scores can range from 10 t0 50, with higher scores representing higher levels of positive affect and with lower scores representing lower levels of negative affect.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="7.8"/>
                    <measurement group_id="O2" value="27.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="1.6"/>
                    <measurement group_id="O2" value="11.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prolonged Abstinence Post Trial</title>
        <description>Abstinence from 2 weeks post quit date to the one month follow up</description>
        <time_frame>1-month follow-up after end of treatment</time_frame>
        <population>Participants (n=14 in TPN + progesterone; n=9 in TPN + placebo) missing breath CO data were coded as &gt; 10 ppm (positive for smoking).</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Abstinence Post Trial</title>
          <description>Abstinence from 2 weeks post quit date to the one month follow up</description>
          <population>Participants (n=14 in TPN + progesterone; n=9 in TPN + placebo) missing breath CO data were coded as &gt; 10 ppm (positive for smoking).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>abstinent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>not abstinent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.6449</p_value>
            <method>Chi-squared</method>
            <method_desc>degrees of freedom = 1</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7172</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1738</ci_lower_limit>
            <ci_upper_limit>2.9594</ci_upper_limit>
            <estimate_desc>Odds ratio represents odds of CO &lt; 10 ppm (negative for smoking) in TPN + progesterone versus TPN + placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prolonged Abstinence Follow up</title>
        <description>Abstinence from 2 weeks post quit date to 3 month follow up (total of 6-8 weeks during the trial and 3 month follow up)</description>
        <time_frame>3-month follow-up after end of treatment</time_frame>
        <population>Participants (n=14 in TPN + progesterone; n=9 in TPN + placebo) missing breath CO data were coded as &gt; 10 ppm (positive for smoking).</population>
        <group_list>
          <group group_id="O1">
            <title>TNP + Progesterone</title>
            <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
          </group>
          <group group_id="O2">
            <title>TNP + Placebo</title>
            <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Abstinence Follow up</title>
          <description>Abstinence from 2 weeks post quit date to 3 month follow up (total of 6-8 weeks during the trial and 3 month follow up)</description>
          <population>Participants (n=14 in TPN + progesterone; n=9 in TPN + placebo) missing breath CO data were coded as &gt; 10 ppm (positive for smoking).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>abstinent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>not abstienent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6449</p_value>
            <method>Chi-squared</method>
            <method_desc>degrees of freedom = 1</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7172</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1738</ci_lower_limit>
            <ci_upper_limit>2.9594</ci_upper_limit>
            <estimate_desc>Odds ratio represents odds of prolonged abstinence in TPN + progesterone versus TPN + placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TNP + Progesterone</title>
          <description>Transdermal Nicotine Patch + Progesterone (200 mgs BID)
Progesterone (200 mgs BID): TNP + Progesterone</description>
        </group>
        <group group_id="E2">
          <title>TNP + Placebo</title>
          <description>Transdermal Nicotine Patch + Placebo (for Progesterone)
Placebo: TNP + Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea, vomiting, diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ER visit for unknown reason</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>wrist and back injury due to fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>3 Menses in one month</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Yonkers, MD</name_or_title>
      <organization>Yale School of Public Health</organization>
      <phone>(203) 764-6621</phone>
      <email>kimberly.yonkers@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

